Y-mAbs Therapeutics Inc.

6.18
-0.01 (-0.16%)
Jan 22, 2025, 3:42 PM - Market open
-0.16%
Bid 6.18
Market Cap 276.80M
Revenue (ttm) 84.86M
Net Income (ttm) -23.95M
EPS (ttm) -0.54
PE Ratio (ttm) -11.44
Forward PE -22.91
Analyst Buy
Ask 6.2
Volume 173,838
Avg. Volume (20D) 320,576
Open 6.20
Previous Close 6.19
Day's Range 6.02 - 6.25
52-Week Range 6.01 - 20.90
Beta 0.67

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 21, 2018
Employees 100
Stock Exchange NASDAQ
Ticker Symbol YMAB

Analyst Forecast

According to 10 analyst ratings, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 272.17% from the latest price.

Buy 90.00%
Hold 0.00%
Sell 10.00%
Stock Forecasts

Next Earnings Release

Y-mAbs Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $26.94M, reflecting a 15.31% YoY growth and earnings per share of -0.12, making a 500.00% increase YoY.
1 month ago
-0.77%
Y-MAbs Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
5 months ago
+10.63%
Y-mAbs Therapeutics shares are trading. The stock may be rebounding after falling earlier in the week on weak earnings and guidance.

We use cookies to ensure that we give you the best experience on our website. Read Privacy Policy.